Steris

Q2 2027
Speakers

Nov 5, 2026 · 34 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good day and welcome to the STERIS PLC second quarter 2027 Financial Results Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on a touchstone phone.

To withdraw your question, please press star, then two. Please note this event is being recorded.
?I would now like to turn the conference over to Julie Winter, Investor Relations. Please go ahead.

Passages & reports (4)
  • Good day and welcome to the STERIS PLC second quarter 2027 Financial Results Conference Ca…
  • To ask a question, you may press star, then one on a touchstone phone. To withdraw your qu…
  • I
  • would now like to turn the conference over to Julie Winter, Investor Relations. Please go …

Speaker 1

Unverified voice label

Thank you, Nick, and good morning, everyone. Speaking on today's call will be Karen Burton, our Senior Vice President and CFO, ?and Dan Crestio, our president and CEO. I do have a few words of caution before we open for cameras from management. This webcast contains time-sensitive information that is accurate only as of today. Any redistribution, retransmission, or rebroadcast of this call without the express written consent of STERIS is strictly prohibited. ?

Some
of the statements made during this review are or may be considered forward looking statements. Many important factors could cause actual results to differ materially from those in the forward looking statements, including, without limitation, those risk factors described in STERIS securities filings. Company does not undertake to update or revise any forward looking statements as a result of new information or future events or developments.

DARIS says SEC filings are available through the company and on our website.
?In addition, on today's call, non-gap financial measures, including adjusted earnings per diluted share, adjusted operating income, constant currency organic revenue growth, and pre-cash flow will be used. Additional information regarding these measures, including definitions, is available in our release, as well as reconciliations between GAAP and non-GAAP financial measures. Non-GAAP financial measures are presented during this call with the intent of providing greater transparency to supplemental financial information used by management and the board of directors in their financial analysis and operational decision making.

With those questions, I will hand the call over to Karen.
?Thank you, Julie, and good morning, everyone. It is my pleasure to

Passages & reports (12)
  • Thank you, Nick, and good morning, everyone. Speaking on today's call will be Karen Burton…
  • and
  • Dan Crestio, our president and CEO. I do have a few words of caution before we open for ca…
  • prohibited.
  • Some
  • of the statements made during this review are or may be considered forward looking stateme…
  • forward looking statements as a result of new information or future events or developments…
  • In
  • addition, on today's call, non-gap financial measures, including adjusted earnings per dil…
  • financial measures. Non-GAAP financial measures are presented during this call with the in…
  • Thank
  • you, Julie, and good morning, everyone. It is my pleasure to

Speaker unclear

?be

Passages & reports (1)
  • be

Speaker 2

Unverified voice label

with you this morning to review the highlights of

Passages & reports (1)
  • with you this morning to review the highlights of

Speaker 1

our second quarter performance. ?For the second quarter, total as reported

Passages & reports (3)
  • our second quarter performance.
  • For
  • the second quarter, total as reported

Speaker 2

revenue grew 9% to $1.6 billion. Constant currency organic revenue grew 8% in the quarter, driven by volume as well as 230 basis points of price. Adjusted gross margin for the quarter was 45.3%, up 100 basis points versus the prior year. Margin expansion was driven primarily by tariff refunds of approximately 20 million during the quarter, which added 130 basis points year over year.

Underlying margins were down slightly as favorable price was more than offset by inflation.

Passages & reports (2)
  • revenue grew 9% to $1.6 billion. Constant currency organic revenue grew 8% in the quarter,…
  • versus the prior year. Margin expansion was driven primarily by tariff refunds of approxim…

Gross tariff costs were approximately $15 million in the second quarter, flat with the prior year. For clarity, tariff refunds are not being allocated to our business segments, but instead

Passages & reports (1)
  • Gross tariff costs were approximately $15 million in the second quarter, flat with the pri…

Speaker 1

are

Passages & reports (1)
  • are

Speaker 2

booked to corporate to enable business segment analysis. Adjusted EBIT margin was 24.6% for the quarter, up 150 basis points from the second quarter last year. Tariff refunds contributed 130 basis points to the increase. Underlying margin improvement benefited from favorable price and volume, partially offset by inflation and investments in the business, including the acceleration of RD spending. We do not expect any material additional tariff refunds during the remainder of fiscal 2027.

Passages & reports (2)
  • booked to corporate to enable business segment analysis. Adjusted EBIT margin was 24.6% fo…
  • margin improvement benefited from favorable price and volume, partially offset by inflatio…

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 2

adjusted effective tax rate in the quarter was 25.3 percent, an increase from 24.5 percent in the second quarter of last year. The increase was primarily driven by unfavorable discrete items. Adjusted net income in the quarter was $286.8 million compared with $244.5 million in the prior ?year. Adjusted earnings per share were $2.94, a 19% increase over $2.47 in the second quarter of last year.

Excluding tariff refunds, adjusted earnings per diluted share grew 13%. Capital
expenditures for the second quarter were $76.1 million, and depreciation and amortization totaled $125.6 million. We ended the quarter with a strong balance sheet reflecting $1.9 billion in total debt. Gross debt to EBITDA at quarter end was approximately $1.1 times. Free cash flow for the first six months was $492.5 million compared with $527.7 million in the prior year period.

Cash flow from operations was six hundred and fifty six point one million
compared with $707.8 million last year. The decline in cash flow was driven primarily by significantly lower contribution from working capital as we utilized cash to build inventory in support of second half shipments, partially offset by higher net income.

Passages & reports (7)
  • adjusted effective tax rate in the quarter was 25.3 percent, an increase from 24.5 percent…
  • $286.8 million compared with $244.5 million in the prior
  • year.
  • Adjusted earnings per share were $2.94, a 19% increase over $2.47 in the second quarter of…
  • expenditures for the second quarter were $76.1 million, and depreciation and amortization …
  • approximately $1.1 times. Free cash flow for the first six months was $492.5 million compa…
  • compared with $707.8 million last year. The decline in cash flow was driven primarily by s…

Share buybacks in the second quarter totaled $100 million or $200 million for the year to date. We have $800 million remaining under our current authorization. During the quarter, we approved an additional restructuring plan covering targeted facility realignment, product rationalization, and select organizational realignment. We anticipate total charges of $45 million, including $10 million in cash expenditures and $35 million in non cash charges.

Approximately $25 million was recorded in the
second quarter. The plan is expected to generate annualized savings of approximately $9 million, with a portion realized in fiscal 2028 ?and the full benefit in subsequent fiscal years. With that, I will now turn the call over to Dan for his remarks.

Passages & reports (5)
  • Share buybacks in the second quarter totaled $100 million or $200 million for the year to …
  • realignment, product rationalization, and select organizational realignment. We anticipate…
  • second quarter. The plan is expected to generate annualized savings of approximately $9 mi…
  • and
  • the full benefit in subsequent fiscal years. With that, I will now turn the call over to D…

Speaker 3

Unverified voice label

Thanks, Karen, and good morning, everyone. Thank you for joining us to hear more about our second quarter 2027 performance and our outlook for the remainder of the year. Karen covered the quarter at a high level, so I'll add some commentary on our segments. Starting with healthcare, constant currency organic revenue grew 7% in the quarter. Our performance reflected solid underlying demand with continued strength in our GI business.

The strength of our portfolio and commercial teams enables us to help our customers navigate a complex operating environment. Service continued its streak of outperformance, growing 10% in the second quarter.

Passages & reports (2)
  • Thanks, Karen, and good morning, everyone. Thank you for joining us to hear more about our…
  • the quarter. Our performance reflected solid underlying demand with continued strength in …

Consumables grew 10%, benefiting from increased customer consumption and driven by share gains, procedural growth and endoscopy, and to a lesser extent, a recent acquisition of GI products. Healthcare capital equipment revenue increased 4% in the quarter, also benefiting from a recent acquisition. Orders remained stable with 1% growth in the second quarter, and our ending backlog increased to $456 million. EBIT margins for healthcare in the quarter decreased 110 basis points to 24%.

Improvements in volume and price were more than offset by inflation, lower productivity, and
longer-term investments we have accelerated on the back of tariff refunds. Turning to AST, constant currency organic revenue grew 5% per the quarter with 5% growth in services as reported, or 6% constant currency. We ended the quarter on solid ground, and early indications suggest that October is holding those gains.

Even margins for AST were 44.7%, a decrease of approximately 60 basis points from the second quarter of last year.
?The decline reflected increased depreciation and inflation, somewhat offset by improved pricing. Constant currency organic revenue increased 18% for life sciences for the quarter. Supporting that growth, capital equipment grew 53%, and consumables increased 9%. Service revenue grew 5%, reflecting strong shipments backlog was $93 million at quarter end, down a bit from prior year.

Margins were a record 44.4%, an increase of approximately 310 basis points, reflecting improvement in
volume, price, productivity, and favorable mix. Reshoring and localization of manufacturing are benefiting our life sciences segment. Turning before we turn to the Outlook, I do want to discuss our recently announced agreement to acquire Exodus Medical, a surgical specialties products business focused on patient and OR staff safety. Exodus Medical is a natural complement to our healthcare portfolio, expanding our consumables offering and the way we support customers in the operating room. ?

The
business is well known for its flagship PinkPad, a single-use surgical patient positioning product, but its portfolio is much broader. ?The product span patient positioning, patient handling and transfer, patient warming, and operating room essentials. This highly clinical, single use portfolio will strengthen our recurring revenue and expand our direct commercial presence in the OR. Exodus has consistently demonstrated impressive growth driven by a steady stream of innovation and highly effective commercial model.

Our go forward model reflects maintaining revenue growth in the mid teens
?and EBIT margins in the low to mid 50s. The competitive clinical position is well defined and supported by clinical studies, AORN guidelines, and a solid innovation pipeline, as well as intellectual property protection for core products. We are very excited about the opportunities as our companies align to better serve customers. Shifting gears to outlook.

Based on our second quarter results and our expectations for the remainder of the year, we are updating our outlook for fiscal 2027. Our total company revenue growth expectations remain unchanged, including as reported
revenue growth of 7 to 8% and constant currency organic growth of 6 to 7%. Our fiscal 2027 earnings per diluted share outlook has been increased to $11.35 to $11.55, compared with our prior range of $11.10 to $11.30.

Passages & reports (18)
  • Consumables grew 10%, benefiting from increased customer consumption and driven by share g…
  • Orders remained stable with 1% growth in the second quarter, and our ending backlog increa…
  • longer-term investments we have accelerated on the back of tariff refunds. Turning to AST,…
  • suggest that October is holding those gains. Even margins for AST were 44.7%, a decrease o…
  • The
  • decline reflected increased depreciation and inflation, somewhat offset by improved pricin…
  • 9%. Service revenue grew 5%, reflecting strong shipments backlog was $93 million at quarte…
  • volume, price, productivity, and favorable mix. Reshoring and localization of manufacturin…
  • patient and OR staff safety. Exodus Medical is a natural complement to our healthcare port…
  • The
  • business is well known for its flagship PinkPad, a single-use surgical patient positioning…
  • The
  • product span patient positioning, patient handling and transfer, patient warming, and oper…
  • growth driven by a steady stream of innovation and highly effective commercial model. Our …
  • and
  • EBIT margins in the low to mid 50s. The competitive clinical position is well defined and …
  • as our companies align to better serve customers. Shifting gears to outlook. Based on our …
  • revenue growth of 7 to 8% and constant currency organic growth of 6 to 7%. Our fiscal 2027…

This includes approximately 18 cents per share benefit from tariff refunds year to date in fiscal 2027. The additional increase in outlook was driven by second quarter outperformance and lower interest. ?From a segment perspective, we continue to expect healthcare, constant currency organic revenue growth of 6 to 7 percent. We now expect AST growth of 6 to 7 percent previously compared to the 7 to 8 percent.

This revision reflects us maintaining our exit rate for the second quarter for the balance of the
?year. Based on the strong first half, we are increasing life science's constant currency organic growth outlook to 9 to 10% compared with 6 to 7% previously. ?This reflects a return to more normalized growth in the second half of the year and the outperformance in the first half led by capital equipment.

All other elements of our most recently provided outlook remained unchanged, but as a reminder, this outlook does not include Exodus Medical, and we will update our expectations after close.

Passages & reports (7)
  • This includes approximately 18 cents per share benefit from tariff refunds year to date in…
  • From
  • a segment perspective, we continue to expect healthcare, constant currency organic revenue…
  • year.
  • Based on the strong first half, we are increasing life science's constant currency organic…
  • This
  • reflects a return to more normalized growth in the second half of the year and the outperf…

Speaker unclear

?This

Passages & reports (1)
  • This

Speaker 3

is a very exciting time at STERIS. The business continues to perform very well, and we are able to prioritize investments in the business that will support our growth for years to come. ?I want to thank all of our associates for continuing to do what they do best, focus on our customers, and strive to do a little better each day. ?That concludes our prepared remarks to the call.

Nick, would you please give the instructions and we can begin the QA?

Passages & reports (5)
  • is a very exciting time at STERIS. The business continues to perform very well, and we are…
  • I
  • want to thank all of our associates for continuing to do what they do best, focus on our c…
  • That
  • concludes our prepared remarks to the call. Nick, would you please give the instructions a…

Speaker 0

Thank ?you. We will now begin the question and answer session. To ask a question, you may press star, then one on your touch tone phone. If you are using a speaker phone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. At this time we'll pause momentarily to assemble the roster.

Passages & reports (4)
  • Thank
  • you.
  • We will now begin the question and answer session. To ask a question, you may press star, …
  • your question, please press star, then two. At this time we'll pause momentarily to assemb…

Questions & answers

Speaker 0

The first question will come from Brett Fishman with KeyBank. Please go ahead.

Passages & reports (1)
  • The first question will come from Brett Fishman with KeyBank. Please go ahead.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 4

Unverified voice label

guys, thank you so much for taking the questions and good morning. Maybe just starting with the acquisition of Exodus Medical definitely seems like a nice fit for Steris and was just curious if you could discuss a little bit more than what you provided on why this was particularly attractive for the company. And then just more broadly, how you think about this new call point as a longer-term opportunity for the healthcare business.

Passages & reports (2)
  • guys, thank you so much for taking the questions and good morning. Maybe just starting wit…
  • then just more broadly, how you think about this new call point as a longer-term opportuni…

Speaker 3

Thanks, Brett. ?I appreciate the question. Yeah, we're very excited about the planned acquisition of Exodus. And you mentioned it, but it gives us a new call point and a real clinical sales force, you know, in the OR, which we really don't have today. I mean, when we sell our surgical infrastructure, our capital products, lights and tables, and ORI, that's more on a build type architectural type cell.

This really gives us an everyday call point and a reason to be in the operating room, which is the beginning of reprocessing or the end of reprocessing, depending on how you look at it, in the total total perioperative loop. So they
have great products, they're high margin, high growth, and consumable, and have had a great trajectory of performance for seven, eight years now, I would say.

The product has a lot of customer acceptance and appreciation. It's supported by AORN, and we just think
it's going to be a great ad for STERS.

Passages & reports (6)
  • Thanks, Brett.
  • I
  • appreciate the question. Yeah, we're very excited about the planned acquisition of Exodus.…
  • tables, and ORI, that's more on a build type architectural type cell. This really gives us…
  • have great products, they're high margin, high growth, and consumable, and have had a grea…
  • it's going to be a great ad for STERS.

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 4

right. Awesome, awesome. And then maybe just one more question on the guidance. I think ?you know the ASC topic has, or sorry, the um applied the applied sterilization technologies topic has just been a little bit of a conversation. And you know, you had the competitor talking about some incremental headwinds in Europe around just overall activity levels. Um was curious if the change to guidance, the slight change to guidance, is uh more to do with ?you know continued inventory dynamics or if you're also seeing some type of you know slowdown or weakening in any particular geographies.

Thank you so

Passages & reports (6)
  • right. Awesome, awesome. And then maybe just one more question on the guidance. I think
  • you
  • know the ASC topic has, or sorry, the um applied the applied sterilization technologies to…
  • guidance, is uh more to do with
  • you
  • know continued inventory dynamics or if you're also seeing some type of you know slowdown …

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 3

Sure thing, Brett. So ?what I would say is this

Passages & reports (3)
  • Sure thing, Brett. So
  • what
  • I would say is this

Speaker unclear

?we

Passages & reports (1)
  • we

Speaker 3

we had a slow start to the year based on really difficult comps. Um as we started in the Q2, which we just ended, obviously, we saw that improve, especially in September, and those improvements continued through in October. So we feel pretty confident in the in the back half that we're going to be, you know, somewhere in the six to eight percent growth for that side of the business.

Um and that's supported by the numbers we've seen thus far. I would not say there's a reason. In fact, I we do obviously do listen to the others' reports, and we actually had better growth or as good
or better growth in Europe last quarter than we did in North America. So I think it's just pockets of different customers and things that happen that cause some things.

So I wouldn't breathe too much into that. In terms of general volume in the US,
?you know, we've we said this before, but we expect we expect it to be procedural growth at the lower end of the range, which is somewhere around 3% instead of the high end of that range, which can be 5%, which drives consumption of yeah, all of our businesses for the most

Passages & reports (5)
  • we had a slow start to the year based on really difficult comps. Um as we started in the Q…
  • you know, somewhere in the six to eight percent growth for that side of the business. Um a…
  • or better growth in Europe last quarter than we did in North America. So I think it's just…
  • you
  • know, we've we said this before, but we expect we expect it to be procedural growth at the…

Speaker unclear

?part. All

Passages & reports (1)
  • part. All

Speaker 4

right, thank you so much again. Appreciate

Passages & reports (1)
  • right, thank you so much again. Appreciate

Speaker unclear

?it.

Passages & reports (1)
  • it.

Speaker 0

The next question will come from Patrick Wood with UBS. Please go ahead.

Passages & reports (1)
  • The next question will come from Patrick Wood with UBS. Please go ahead.

Speaker unclear

?Amazing. Uh thanks guys. Um

Passages & reports (1)
  • Amazing. Uh thanks guys. Um

Speaker 4

maybe

Passages & reports (1)
  • maybe

Speaker unclear

?for the

Passages & reports (1)
  • for the

Speaker 5

Unverified voice label

first one, uh just to jump on AST again as as volumes start coming back. You know, where are we at very roughly or qualitatively in terms of utilization? I'm sure ?EO is pretty tight, but you know, obviously things like gamma, the fixed costs of you know the half-life that side of things, you know, you can get a lot of talk as volumes begin coming back, moving through the PL on margins.

So like are we going to see as volumes begin to come back a little bit
of um leverage coming through on those facilities? I'm not sure where utilization sits today versus uh versus history. Thanks.

Passages & reports (4)
  • first one, uh just to jump on AST again as as volumes start coming back. You know, where a…
  • EO is pretty tight,
  • but you know, obviously things like gamma, the fixed costs of you know the half-life that …
  • of um leverage coming through on those facilities? I'm not sure where utilization sits tod…

Speaker 3

Well, you know, total utilization across the network is pretty high, but we have room effectively everywhere because the volumes are slightly less aggressive than what we thought they were gonna be at the beginning of the year. So as volumes do ?come back on the existing infrastructure that we have in place and capacity that we have installed, because we never slowed our isotope loading or anything like that, because if you miss it, you miss it forever.

So we've kept up with our loadings. We have adequate capacity to take on the increased demand as it
flows through. And yes, you're right. The difference of a couple percentage points, it makes an awfully big difference in terms of drop-through at the margin line. And you know, some of that's offset that we've got some new facilities that are in ramp up mode. ?

Um
so those obviously aren't contributing margin at the same level as a a very mature facility. Um so that has some of somewhat of a dilute effect, but those are for the most part already in the PL. And so any improvement in volume should show through.

Passages & reports (6)
  • Well, you know, total utilization across the network is pretty high, but we have room effe…
  • come
  • back on the existing infrastructure that we have in place and capacity that we have instal…
  • flows through. And yes, you're right. The difference of a couple percentage points, it mak…
  • Um
  • so those obviously aren't contributing margin at the same level as a a very mature facilit…

Speaker 5

Super clear. Thank you. And then just quickly, the um ?on the healthcare business, obviously uh uh of the capital equipment line, a chunk of it is essentially not optional, you know, obviously because it's gonna have to be sterilizing. But you know, you have some that's a little bit more, you know, surgically connected in that side. And I guess ?it maybe it's a bit off the beaten path, but the 340B reform rules were kind of finalized and looked like last night.

You know, we're all debating on what effect that could have on hospitals or those hospitals' PLs that were relying on it a little bit.
?I don't know. Have you heard anything from customers in terms of their CapEx outlook, whether that would affect them, or is it just more of the

Passages & reports (7)
  • Super clear. Thank you. And then just quickly, the um
  • on
  • the healthcare business, obviously uh uh of the capital equipment line, a chunk of it is e…
  • it
  • maybe it's a bit off the beaten path, but the 340B reform rules were kind of finalized and…
  • I don't
  • know. Have you heard anything from customers in terms of their CapEx outlook, whether that…

Speaker unclear

?same?

Passages & reports (1)
  • same?

Speaker 3

It's more of the same. In fact, we actually had a a really great order recorder on our surgical products this past quarter. So ?uh and yeah, there's there's a bit of a shift going on in in healthcare today where you know the plan is as as our population ages here domestically, anyways, hospitals are gonna have to push healthy patients out to their their ASC networks for procedures.

And they're gonna have to take higher acuity patients into
the large acute care facilities, which are gonna require more capacity uh in those locations. Um so we haven't we haven't seen any slowdown on the capital whatsoever. Um our backlog in healthcare is pretty much near record if you exclude the supply chain crisis a few years ago. But so we we feel pretty good about

Passages & reports (5)
  • It's more of the same. In fact, we actually had a a really great order recorder on our sur…
  • uh
  • and yeah, there's there's a bit of a shift going on in in healthcare today where you know …
  • the large acute care facilities, which are gonna require more capacity uh in those locatio…
  • good about

Speaker unclear

?that.

Passages & reports (1)
  • that.

Speaker 3

Thanks fine. I'll

Passages & reports (1)
  • Thanks fine. I'll

Speaker unclear

?shut up now.

Passages & reports (1)
  • shut up now.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Mac Etalk with Stevens. Please go ahead.

Passages & reports (1)
  • next question will come from Mac Etalk with Stevens. Please go ahead.

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 3

good morning and thank you for taking my questions.

Passages & reports (1)
  • good morning and thank you for taking my questions.

Speaker unclear

?Maybe just starting on the life

Passages & reports (1)
  • Maybe just starting on the life

Speaker 6

Unverified voice label

sciences segment. I you know you previously disclosed that onshoring could be more of a longer term benefit. But given some of your prepared remarks, can you just expand on what you're seeing today and how you're thinking around some of these broader macro factors are developing versus maybe at the start of the

Passages & reports (1)
  • sciences segment. I you know you previously disclosed that onshoring could be more of a lo…

Speaker unclear

?year?

Passages & reports (1)
  • year?

Speaker 3

Yes, I think I think the difference today is that some of the plans that are that were previously announced by our customers for expansion in the U.S. and also some of the juxtaposition of manufacturing in Europe were just that. But now they're starting to materialize, and we're starting to see orders from a capital equipment perspective, but but also we're starting to see requests for work on the on our chemistry side of the uh side of the business as well.

Now, having said that, this past quarter was the outperformance there, you know, we had a great order shipments quarter, but there was one particular order that
really made a big difference that was in excess of ten million dollars for a single customer. So that would that one moved the needle. It's that one won't be replaced on a quarterly basis, but nonetheless, we expect great performance by life science throughout the end of the

Passages & reports (3)
  • Yes, I think I think the difference today is that some of the plans that are that were pre…
  • capital equipment perspective, but but also we're starting to see requests for work on the…
  • really made a big difference that was in excess of ten million dollars for a single custom…

Speaker unclear

?year.

Passages & reports (1)
  • year.

Speaker 6

Got it, I appreciate that. And then maybe just quickly touching on tariffs as well. I I think twenty y'all cited twenty four million as being the total pool ?of available tariff refunds uh for the year. Has that shifted at all? Is uh is that available pool widened? I know you're not factoring anything ?in in anything additional in the guide, obviously, ?but uh I just want to get a sense

Passages & reports (7)
  • Got it, I appreciate that. And then maybe just quickly touching on tariffs as well. I I th…
  • of
  • available tariff refunds uh for the year. Has that shifted at all? Is uh is that available…
  • in
  • in anything additional in the guide, obviously,
  • but uh
  • I just want to get a sense

Speaker unclear

?there.

Passages & reports (1)
  • there.

Speaker 1

Thanks,

Passages & reports (1)
  • Thanks,

Speaker unclear

?Mac.

Passages & reports (1)
  • Mac.

Speaker 2

Yeah, this is Karen. The tariffs that we have received of twenty four million is what we expect to receive. The total AIPA tariffs paid last year were 27. ?So we've got about 3 million where there's just no refund program right now to recoup those. So we are not projecting receipt of

Passages & reports (3)
  • Yeah, this is Karen. The tariffs that we have received of twenty four million is what we e…
  • So
  • we've got about 3 million where there's just no refund program right now to recoup those. …

Speaker unclear

?those. Thank

Passages & reports (1)
  • those. Thank

Speaker 6

you for taking my questions.

Passages & reports (1)
  • you for taking my questions.

Speaker 0

Again, if you have a question, please press star and then one. The next question will come from Michael Polark with Wolf Research. Please go ?ahead. Hey good morning. Uh thank you for taking the questions.

Passages & reports (3)
  • Again, if you have a question, please press star and then one. The next question will come…
  • ahead. Hey
  • good morning. Uh thank you for taking the questions.

Speaker unclear

?Dan, curious

Passages & reports (1)
  • Dan, curious

Speaker 0

if you

Passages & reports (1)
  • if you

Speaker unclear

?could

Passages & reports (1)
  • could

Speaker 6

bridge healthcare consumables

Passages & reports (1)
  • bridge healthcare consumables

Speaker 0

growth. I know there's small MA flowing through, ?but seven percent last year, call it high single digits solidly year ?to date,

Passages & reports (5)
  • growth. I know there's small MA flowing through,
  • but
  • seven percent last year, call it high single digits solidly year
  • to
  • date,

Speaker unclear

?with

Passages & reports (1)
  • with

Speaker 6

AST volumes being muted. What's the disconnect there? Why is healthcare consumables growth You know.

Passages & reports (1)
  • AST volumes being muted. What's the disconnect there? Why is healthcare consumables growth…

Speaker unclear

?Yeah.

Passages & reports (1)
  • Yeah.

Speaker 3

Thanks, Mike. At a high level,

Passages & reports (1)
  • Thanks, Mike. At a high level,

Speaker 6

kind of growing at a much higher rate and ASD volumes still kind of seem

Passages & reports (1)
  • kind of growing at a much higher rate and ASD volumes still kind of seem

Speaker unclear

?tempered.

Passages & reports (1)
  • tempered.

Speaker 3

There's there's an easy explanation, Mike. So the reality is over the last few years we've placed an awful lot of dedicated chemistry equipment um out there. Uh and you know that those are things like B pros and our washers and obviously AERs. And as a result, that that share gains that we've been delivering on the capital side is now converting into consumables growth.

In addition to that, you know, a lot of our chemistry's franchise in consumables and healthcare is weighted towards endoscopy. It's you know the chemistry that goes through our automatic endoscope or processors. And we've had a really great year thus far on
placements of new machines. Um and in addition to that, the general growth rate of endoscopy has remained strong. When I when I talk about general growth rate, I mean procedures has remained mid to high single digits consistently.

so so there's a bit of a bias in our healthcare consumables business towards towards endoscopy.

Passages & reports (3)
  • There's there's an easy explanation, Mike. So the reality is over the last few years we've…
  • delivering on the capital side is now converting into consumables growth. In addition to t…
  • placements of new machines. Um and in addition to that, the general growth rate of endosco…

Speaker unclear

?I'll

Passages & reports (1)
  • I'll

Speaker 3

follow up on that uh that was just one of my other topics. ?Um so

Passages & reports (3)
  • follow up on that uh that was just one of my other topics.
  • Um
  • so

Speaker unclear

?heard

Passages & reports (1)
  • heard

Speaker 6

yes the just now and then in your prepared remark the GI enthusiasm reaffirmed. Um

Passages & reports (1)
  • yes the just now and then in your prepared remark the GI enthusiasm reaffirmed. Um

Speaker unclear

?there

Passages & reports (1)
  • there

Speaker 6

is a competitor there that has some challenges in the US, Olympus, I'll say the name so you don't have to um obviously you don't sell scopes, ?but um you know they sell reprocessors and maybe some accessories and ?ha has that been a benefit worth spiking out in your GI business or no? You this is ?this is not share

Passages & reports (7)
  • is a competitor there that has some challenges in the US, Olympus, I'll say the name so yo…
  • but
  • um you know they sell reprocessors and maybe some accessories and
  • ha
  • has that been a benefit worth spiking out in your GI business or no? You this is
  • this
  • is not share

Speaker 4

game

Passages & reports (1)
  • game

Speaker 6

for execution and market.

Passages & reports (1)
  • for execution and market.

Speaker unclear

?Like

Passages & reports (1)
  • Like

Speaker 3

it's been it's been a benefit, but it's minor. I mean it's it it's you know it's it's been a quarter or two of improved AER sales, but I mean there's there's an awful lot of those machines out there still. Um, you know, so over time, you know, we'll we'll continue to do do to do well, I'm sure. Um but like I said, it's been a it's been a help, but it's been insignificant in the gram scheme of

Passages & reports (2)
  • it's been it's been a benefit, but it's minor. I mean it's it it's you know it's it's been…
  • to do well, I'm sure. Um but like I said, it's been a it's been a help, but it's been insi…

Speaker unclear

?things.

Passages & reports (1)
  • things.

Speaker 3

Thank ?you. Yep.

Passages & reports (3)
  • Thank
  • you.
  • Yep.

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

next question will come from Mike Matzen with Needham Co. Please go ahead.

Passages & reports (1)
  • next question will come from Mike Matzen with Needham Co. Please go ahead.

Speaker 5

Yeah, thanks. So ?just want to ask another one on Exodus Medical. Um by our rough math, it seems like this could be a fairly accretive acquisition to EPS. I mean, we're coming up

Passages & reports (3)
  • Yeah, thanks. So
  • just want
  • to ask another one on Exodus Medical. Um by our rough math, it seems like this could be a …

Speaker 4

with kind of three to five percent EPS accretion on an annual basis. I mean, this business has extremely high operating

Passages & reports (1)
  • with kind of three to five percent EPS accretion on an annual basis. I mean, this business…

Speaker 5

margins. I don't know if you're willing to comment on that, or I assume you'll maybe you'll give us more information when you actually close the deal.

Passages & reports (1)
  • margins. I don't know if you're willing to comment on that, or I assume you'll maybe you'l…

Speaker 2

Yes, Mike, this is Karen. We will give updated guidance once we close the deal. And certainly we expect it to be a creative top to bottom revenue margins and EPS. But I would encourage you to make sure you're including all of the interest costs as we

Passages & reports (1)
  • Yes, Mike, this is Karen. We will give updated guidance once we close the deal. And certai…

Speaker 1

are funding ?this deal with debt.

Passages & reports (3)
  • are funding
  • this deal
  • with debt.

Speaker 5

Okay.

Passages & reports (1)
  • Okay.

Speaker unclear

?Yeah, I mean we were assuming around like a 6%

Passages & reports (1)
  • Yeah, I mean we were assuming around like a 6%

Speaker 3

interest rate. Does

Passages & reports (1)
  • interest rate. Does

Speaker unclear

?that

Passages & reports (1)
  • that

Speaker 5

sound in the ballpark?

Passages & reports (1)
  • sound in the ballpark?

Speaker 1

It certainly

Passages & reports (1)
  • It certainly

Speaker unclear

?does.

Passages & reports (1)
  • does.

Speaker 5

Okay. All right. And then ?there was some commentary earlier in um September at a investor conference about de stocking in the AST business, you know, by your customers. So ?I I think you've kind of addressed that in a way by saying you saw it get better in October. ?But I just

Passages & reports (7)
  • Okay. All right. And then
  • there
  • was some commentary earlier in um September at a investor conference about de stocking in …
  • I
  • I think you've kind of addressed that in a way by saying you saw it get better in October.
  • But
  • I just

Speaker unclear

?wanted to see if you could

Passages & reports (1)
  • wanted to see if you could

Speaker 5

elaborate on that commentary a little bit. Thanks.

Passages & reports (1)
  • elaborate on that commentary a little bit. Thanks.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

sure, Mike. Thanks. Yeah, I think at this point we're confident to say that the stocking has ended. We think it washed itself out ?in the in the last quarter that we just completed. And then we've we've seen more normalized growth at the back end of that quarter, and then we have pretty good revenue growth in October which we normally don't hit on but given it's relevant as to what we've been saying for the last you know six months that first half's going to be tough and then we got easier comps in the second um we're confident in delivering that message.

Passages & reports (4)
  • sure, Mike. Thanks. Yeah, I think at this point we're confident to say that the stocking h…
  • in
  • the in the last quarter that we just completed. And then we've we've seen more normalized …
  • six months that first half's going to be tough and then we got easier comps in the second …

Speaker 5

Okay thank

Passages & reports (1)
  • Okay thank

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 3

yep

Passages & reports (1)
  • yep

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 0

next question will come from Jason Bednar with Piper Sandler. Please go ahead

Passages & reports (1)
  • next question will come from Jason Bednar with Piper Sandler. Please go ahead

Speaker unclear

?everyone thanks for the questions I'm gonna

Passages & reports (1)
  • everyone thanks for the questions I'm gonna

Speaker 7

Unverified voice label

try one here on AST that's a little bit of a follow-up to some other questions. But just for clarity, so you change in growth guidance here, it's a function of some softer procedure volumes, I think. ?But can can you put a finer point on what you're expecting in guidance with respect to volume growth across your US and European customers? Are you assuming are you assuming the better volume growth, the better, better performance in the business that you referenced, Dan, in September and October, that that persists for the rest of your fiscal year?

or what's the sensitivity on improving or softening from here, knowing that the macro still has a layer of uncertainty to

Passages & reports (4)
  • try one here on AST that's a little bit of a follow-up to some other questions. But just f…
  • But can
  • can you put a finer point on what you're expecting in guidance with respect to volume grow…
  • your fiscal year? or what's the sensitivity on improving or softening from here, knowing t…

Speaker unclear

?it?

Passages & reports (1)
  • it?

Speaker 4

Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

I it's honestly Jason, thanks for the question. It's it's it's kind of simple math. And what I mean by that is, ?you know, last year, first half of the year that we were comparing to, we we grew over 10%, right? ?And then that slowed significantly if you go back and look at the constant currency organic numbers to you know mid to low single digits.

So just the comps and growth become a lot easier to get to as we started seeing destocking
?in the third quarter of last year. Um so as a result of that, and and based on what we think is a very stable healthcare operating environment right now, we're confident that uh against those easier comps, we should be d be able to deliver much higher than we did in the first half.

Passages & reports (7)
  • I it's honestly Jason, thanks for the question. It's it's it's kind of simple math. And wh…
  • you
  • know, last year, first half of the year that we were comparing to, we we grew over 10%, ri…
  • And
  • then that slowed significantly if you go back and look at the constant currency organic nu…
  • in
  • the third quarter of last year. Um so as a result of that, and and based on what we think …

Speaker 7

All right, maybe maybe one follow up to that and then I got a separate question. But yeah, I think a lot of investors are really trying to understand like a little bit of the sell in, sell out dynamic on what you're seeing and understanding your layer removed from the the sell out if you will the actual procedure volumes. I mean is are you seeing anything different that's shifting just because there is a lot of you know information that's flowing out there suggesting some softer volume.

So I guess just again trying to understand if there's anything there. And then the the separate question here maybe you
know uh Karen this is for you I mean can you talk about what's stimulating another restructuring program. ?You know just strategically it seems like you know these are maybe becoming a little bit more common the last few years. Is so is something changing with respect to how you're approaching uh operations and your portfolio.

Passages & reports (5)
  • All right, maybe maybe one follow up to that and then I got a separate question. But yeah,…
  • you will the actual procedure volumes. I mean is are you seeing anything different that's …
  • know uh Karen this is for you I mean can you talk about what's stimulating another restruc…
  • You
  • know just strategically it seems like you know these are maybe becoming a little bit more …

Speaker unclear

?Yeah

Passages & reports (1)
  • Yeah

Speaker 3

thanks Chase I'll I'll start on your question on the volumes. You know the you talked you use the word softer volumes and and I think this is way, way overplayed. I mean ?the fact of the matter is that there are some highly elective procedures that have been and will get deferred. And some some of our peers in different segments of highly elected products have talked about ?that.

Some have contradicted each
?other as well, so in terms of what they're seeing. So I I think that that is what it is right now. There's still great growth going on in healthcare and you know in terms of general procedures. We've I've said ?and I've been clear that it's at the low end of the range, meaning if we we always sort of assume somewhere between two and a half, three and five percent procedure growth rate, especially for North America, we're probably down towards three right now, you know, um ?but it's still growth rate, right?

It's not negative. Um we're flat. And and we have a mountain of data from all the SPDs, steel processing departments that we run across North America and the UK and other places in Europe, that says that the number of trays and consumption is is up. So based on
everything that we're looking ?at, although there's economic stress clearly for our customers in particular in North America, um there's still there's still high level of demand.

Passages & reports (14)
  • thanks Chase I'll I'll start on your question on the volumes. You know the you talked you …
  • the
  • fact of the matter is that there are some highly elective procedures that have been and wi…
  • that.
  • Some have contradicted each
  • other
  • as well, so in terms of what they're seeing. So I I think that that is what it is right no…
  • and
  • I've been clear that it's at the low end of the range, meaning if we we always sort of ass…
  • but
  • it's still growth rate, right? It's not negative. Um we're flat. And and we have a mountai…
  • everything that we're looking
  • at,
  • although there's economic stress clearly for our customers in particular in North America,…

Speaker unclear

?All

Passages & reports (1)
  • All

Speaker 2

right, Jason. I will talk

Passages & reports (1)
  • right, Jason. I will talk

Speaker 1

to you a

Passages & reports (1)
  • to you a

Speaker 2

bit about

Passages & reports (1)
  • bit about

Speaker 1

restructuring.

Passages & reports (1)
  • restructuring.

Speaker 2

So the new plan is targeted in terms

Passages & reports (1)
  • So the new plan is targeted in terms

Speaker unclear

?of

Passages & reports (1)
  • of

Speaker 1

some smaller

Passages & reports (1)
  • some smaller

Speaker 2

actions. That would include some key components like elimination of a single use urology scope from our product portfolio. So the costs include disposal of inventory, termination of supply contracts, impairment of intangible assets. Another key component is some small site consolidation, including transition of production of our sterility assurance products to the new MENAR manufacturing site that was announced early in fiscal 26. The plan that was announced in August, in conjunction with the announcement of a formulated chemistry center of excellence, was 100% focused on that action and the impact of that center of excellence.

So we kept this these other actions separate so that it was clear what we were doing and the timing of those actions. And
?you know, as as you said, this is a little

Passages & reports (5)
  • actions. That would include some key components like elimination of a single use urology s…
  • some small site consolidation, including transition of production of our sterility assuran…
  • announcement of a formulated chemistry center of excellence, was 100% focused on that acti…
  • you
  • know, as as you said, this is a little

Speaker 1

bit unusual for us. We've got two announced this year. We we you know had the Bordeaux

Passages & reports (1)
  • bit unusual for us. We've got two announced this year. We we you know had the Bordeaux

Speaker 2

restructuring ?a couple of years ago now. And I would say when you when you blink those together, what you're seeing is a focus on really challenging our portfolio and our manufacturing and distribution network. And that's the key driver behind all three of these plans.

Passages & reports (3)
  • restructuring
  • a
  • couple of years ago now. And I would say when you when you blink those together, what you'…

Speaker 7

All right. Thank you both.

Passages & reports (1)
  • All right. Thank you both.

Speaker 3

Thanks

Passages & reports (1)
  • Thanks

Speaker 0

The next question is a follow up from Michael Polak of Wolf Research. Please go

Passages & reports (1)
  • The next question is a follow up from Michael Polak of Wolf Research. Please go

Speaker unclear

?ahead. Thank

Passages & reports (1)
  • ahead. Thank

Speaker 6

you for taking the follow up. One more on life sciences. Look, I heard the comment, Dan, um one large order 10 million, loud and clear, ?but it was 18% segment growth, 50% in capital. Something was good. You said onshoring localization of supply chains. Heard, we know that's a mega trend. I would say the feedback from bioprocessing as an example, somewhat mixed ?and still slow going.

So
?I I want to ask if you think there could be something else here. And the other topic in tools land is these so-called self-driving labs, as

Passages & reports (7)
  • you for taking the follow up. One more on life sciences. Look, I heard the comment, Dan, u…
  • but it
  • was 18% segment growth, 50% in capital. Something was good. You said onshoring localizatio…
  • and
  • still slow going. So
  • I
  • I want to ask if you think there could be something else here. And the other topic in tool…

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 0

know, Claude starts doing experimentation. And my joke is Claude will make the beakers dirt dirt

Passages & reports (1)
  • know, Claude starts doing experimentation. And my joke is Claude will make the beakers dir…

Speaker 6

dirty too, and someone will have to clean them. ?D do you see evidence that that kind of theme is an opportunity for life sciences beyond reshoring? Thank

Passages & reports (3)
  • dirty too, and someone will have to clean them.
  • D
  • do you see evidence that that kind of theme is an opportunity for life sciences beyond res…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Thanks, Mike. Um, yeah, we do see that as an opportunity. Clearly, but I would say is

Passages & reports (1)
  • Thanks, Mike. Um, yeah, we do see that as an opportunity. Clearly, but I would say is

Speaker 4

it's ?not something that's

Passages & reports (3)
  • it's
  • not
  • something that's

Speaker 3

registering yet ?in our order book or anything like that. But it is as that trend does continue, I think the way we produce aseptic pharmaceuticals will change over time. And I think that Steris will be in a great position to adapt to that. So I think what we're seeing on that the life science, you know, um order intake and shipments as it relates to capital ?is just some pent-up demand too from a couple years ?of of under buying in the pharmaceutical sector, and and now there's just a little bit of catch-up.

So we're getting to benefit from

Passages & reports (8)
  • registering yet
  • in
  • our order book or anything like that. But it is as that trend does continue, I think the w…
  • um order intake and shipments as it relates to capital
  • is
  • just some pent-up demand too from a couple years
  • of
  • of under buying in the pharmaceutical sector, and and now there's just a little bit of cat…

Speaker unclear

?that.

Passages & reports (1)
  • that.

Speaker 6

Thank

Passages & reports (1)
  • Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

This concludes our question and answer session. ?I would like to turn the conference back over to Julie Winter for any closing remarks.

Passages & reports (3)
  • This concludes our question and answer session.
  • I
  • would like to turn the conference back over to Julie Winter for any closing remarks.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 2

you all for

Passages & reports (1)
  • you all for

Speaker 1

taking the time to join us this morning to learn more about the quarter ?and our outlook for the year. ?We do have quite a few conferences coming up this fall. I look forward to seeing many of you on the road.

Passages & reports (5)
  • taking the time to join us this morning to learn more about the quarter
  • and
  • our outlook for the year.
  • We
  • do have quite a few conferences coming up this fall. I look forward to seeing many of you …

Speaker unclear

?The

Passages & reports (1)
  • The

Speaker 0

conference is now concluded. Thank you for attending today's presentation. You may now disconnect.

Passages & reports (1)
  • conference is now concluded. Thank you for attending today's presentation. You may now dis…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 0. Unassigned words: 170. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T00:53:11.793Z.
Transcript version v1-2b4835ffae50536d7d71 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.